Hero

Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies

1

Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies

Celyad to present CYAD-01 solid tumor clinical updates and pre-clinical pipeline data at the 2018 SITC Annual Meeting

2

Celyad to present CYAD-01 solid tumor clinical updates and pre-clinical pipeline data at the 2018 SITC Annual Meeting

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies

Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies

Celyad to present CYAD-01 solid tumor clinical updates and pre-clinical pipeline data at the 2018 SITC Annual Meeting

Celyad to present CYAD-01 solid tumor clinical updates and pre-clinical pipeline data at the 2018 SITC Annual Meeting

Transparency notification of Victory Capital Management Inc. (Article 14 of the Law of 2 May 2007)

Transparency notification of Victory Capital Management Inc. (Article 14 of the Law of 2 May 2007)

Discover all news

Carousel

Social Feed

"CAR-T is changing the treatment paradigm for cancer by creating targeted treatments that are specific to cancer ce… https://t.co/rM46CoQ45W

22 hours ago

"CAR-T is changing the treatment paradigm for cancer by creating targeted treatments that are specific to cancer ce… https://t.co/rM46CoQ45W

"La ligne directrice c'est la thérapie cellulaire", interview de Patrick Jeanmart lors de la Tv rencontre les dirig… https://t.co/1pXXYrIrSe

1 day ago

"La ligne directrice c'est la thérapie cellulaire", interview de Patrick Jeanmart lors de la Tv rencontre les dirig… https://t.co/1pXXYrIrSe

Shooting an interview of Christian Homsy, CEO of @CelyadSA , for @pharmabe #interview #CEO #reportage https://t.co/Sf0JkTzzKc

1 week ago

Shooting an interview of Christian Homsy, CEO of @CelyadSA , for @pharmabe #interview #CEO #reportage https://t.co/Sf0JkTzzKc

RT @HorizonGenomics: .@CelyadSA Announces Exclusive Agreement for Horizon Discovery’s #shRNA Platform to Develop Next-Generation Allogeneic…

1 week ago

RT @HorizonGenomics: .@CelyadSA Announces Exclusive Agreement for Horizon Discovery’s #shRNA Platform to Develop Next-Generation Allogeneic…

"CAR-T is changing the treatment paradigm for cancer by creating targeted treatments that are specific to cancer ce… https://t.co/rM46CoQ45W

22 hours ago

"CAR-T is changing the treatment paradigm for cancer by creating targeted treatments that are specific to cancer ce… https://t.co/rM46CoQ45W

"La ligne directrice c'est la thérapie cellulaire", interview de Patrick Jeanmart lors de la Tv rencontre les dirig… https://t.co/1pXXYrIrSe

1 day ago

"La ligne directrice c'est la thérapie cellulaire", interview de Patrick Jeanmart lors de la Tv rencontre les dirig… https://t.co/1pXXYrIrSe

Shooting an interview of Christian Homsy, CEO of @CelyadSA , for @pharmabe #interview #CEO #reportage https://t.co/Sf0JkTzzKc

1 week ago

Shooting an interview of Christian Homsy, CEO of @CelyadSA , for @pharmabe #interview #CEO #reportage https://t.co/Sf0JkTzzKc

RT @HorizonGenomics: .@CelyadSA Announces Exclusive Agreement for Horizon Discovery’s #shRNA Platform to Develop Next-Generation Allogeneic…

1 week ago

RT @HorizonGenomics: .@CelyadSA Announces Exclusive Agreement for Horizon Discovery’s #shRNA Platform to Develop Next-Generation Allogeneic…